Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA5A | P35218 | 4/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | CA3 | P07451 | 2/20 | 0.47 |
| ▸ | CA6 | P23280 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347020 | 0.88 | PTGS2 (0.58) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL5312529 | 0.88 | PTGS2 (0.58) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL2462524 | 0.86 | PTGS2 (0.60) | PTGS2PTGS1CHRNA7CA1CA2 | |
| SCHEMBL1123783 | 0.86 | PTGS2 (0.61) | PTGS2PTGS1PDPK1CA1CA2 | |
| SCHEMBL2839074 | 0.84 | CHRNA7 (0.53) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL5309196 | 0.84 | CHRNA7 (0.66) | PTGS2PTGS1CHRNA7CA1CA2 | |
| SCHEMBL5314124 | 0.84 | CHRNA7 (0.66) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL347440 | 0.84 | CHRNA7 (0.66) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL348901 | 0.84 | PTGS2 (0.52) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL29456522 | 0.84 | PTGS2 (0.52) | PTGS2PTGS1PDPK1CHRNA7CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0927555-B1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumours, tumour-related disorders and cachexia | DAIICHI SANKYO CO LTD (JP) | 2011-10-05 | — | — | EP | claimed |
| US-20050014814-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED (JP) | 2005-01-20 | — | — | US | claimed |
| EP-0927555-A1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia | Sankyo Company Limited (JP) | 1999-07-07 | — | — | EP | claimed |
| CN-108601839-A | Bcl-2 inhibitor and MEK inhibitor combination for the treatment of cancer | 基因泰克公司 | 2018-09-28 | — | — | CN | disclosed |
| CN-108175749-A | The solid dispersions of melt extrusion containing cell death inducer | 艾伯维爱尔兰无限公司 | 2018-06-19 | — | — | CN | disclosed |
| CN-103282025-B | Melt-extruded solid dispersions containing apoptosis-inducing agents | 艾伯维爱尔兰无限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-104684906-B | Nampt inhibitor | 艾伯维公司 | 2017-06-09 | — | — | CN | disclosed |
| CN-106456602-A | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2017-02-22 | — | — | CN | disclosed |
| CN-106074391-A | Orally administered pharmaceutical dosage form for 2 group inhibitors of BCL | 雅培股份有限两合公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-102695507-A | Combination therapy for treating cancer and diagnostic assays for use therein | ABBOTT LAB | 2012-09-26 | — | — | CN | disclosed |
| EP-0927555-B1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumours, tumour-related disorders and cachexia | DAIICHI SANKYO CO LTD (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-7745481-B2 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-06-29 | — | — | US | disclosed |
| EP-0799823-B1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | DAIICHI SANKYO CO LTD (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-RE39420-E1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-12-05 | — | — | US | disclosed |
| US-6887893-B1 | Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20050014814-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED (JP) | 2005-01-20 | — | — | US | disclosed |
| US-20050004109-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED | 2005-01-06 | — | — | US | disclosed |
| EP-0927555-A1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia | Sankyo Company Limited (JP) | 1999-07-07 | — | — | EP | disclosed |
| US-5908858-A | OSTEOPOROSIS; LEUKOTRIENE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1999-06-01 | — | — | US | disclosed |
| EP-0799823-A1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1997-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014814-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | CPT1B, PYGM, PTGES2 | PTGS2 4/4885PTGS1 6/4885PDPK1 997/4885 |
| US-20050004109-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | CPT1B, PYGM, PTGES2 | PTGS2 4/4885PTGS1 6/4885PDPK1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.